Aging-driven metabolic abnormalities remodel intercellular communication through the gut–liver–heart axis and may promote coronary artery disease: the key role of bile acid metabolism - Report - MDSpire

Aging-driven metabolic abnormalities remodel intercellular communication through the gut–liver–heart axis and may promote coronary artery disease: the key role of bile acid metabolism

  • By

  • Wei Chen

  • Yue Sun

  • Chu-fan Meng

  • Si-tong Wu

  • Xin-yi Jiang

  • Xian-meng Meng

  • Qing-feng Wang

  • July 6, 2026

  • 0 min

Share

Metabolic Changes Associated with Aging Alter Intercellular Interactions via the Gut–Liver–Heart Axis and May Contribute to Coronary Artery Disease

Background

Coronary artery disease (CAD) is the leading cause of cardiovascular mortality globally, with its prevalence increasing significantly in older populations. Aging is identified as a strong independent risk factor for CAD, with cellular senescence and chronic inflammation playing critical roles.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • Aging promotes coronary artery disease through immunometabolic remodeling of the gut–liver–heart axis.
  • Senescent cells contribute to chronic systemic inflammation via the senescence-associated secretory phenotype (SASP).
  • Age-related dysbiosis affects bile acid metabolism, impacting gut barrier integrity and promoting metabolic endotoxemia.
  • Altered signaling in the liver amplifies systemic inflammation and contributes to vascular dysfunction.

Clinical Implications

Understanding the role of bile acid metabolism and the gut–liver–heart axis in aging can inform the development of targeted therapies for coronary artery disease. Clinicians should consider the implications of cellular senescence and chronic inflammation in older patients when assessing cardiovascular risk.

Conclusion

The interplay between aging, bile acid metabolism, and chronic inflammation provides a crucial framework for understanding coronary artery disease in older adults. Further research is needed to explore potential therapeutic interventions.

Related Resources & Content

  1. Frontiers in Cardiovascular Medicine, 2026 -- Beyond Metabolism and Blood Flow: Toward an Inflammation-Metabolism Axis Paradigm for Herbal Medicine in Obesity-Related Coronary Heart Disease
  2. Frontiers in Endocrinology, 2026 -- Bile acids and bile acid modification in health and disease: from novel modifications to therapeutic interventions
  3. Frontiers in Endocrinology, 2026 -- Prospective association between biological aging and risk of hospital-diagnosed MASLD: evidence from the UK Biobank
  4. Frontiers in Immunology — Revisiting Intervertebral Disc Degeneration: Lipid Metabolism Disorders as Overlooked Contributors to Complex Pathology
  5. ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol
  6. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
  7. First-ever guideline on cardiovascular-kidney-metabolic syndrome issued
  8. https://www.escardio.org/static-file/Escardio/Guidelines/Products/Slide%20sets/2025/2025%20official%20slides_Dyslipidaemias.pdf
  9. Top Takeaways from the 2026 American Heart Association Heart Disease and Stroke Statistics
  10. Ez-PAVE: Hitting Lower LDL-C Target Reduces Major CV Events - American College of Cardiology
  11. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial | JACC
  12. CORALreef Lipids: Oral PCSK9 Inhibitor Enlicitide Reduces LDL-C in High-Risk Patients - American College of Cardiology
  13. Final Follow-Up
  14. Reduced Systemic Levels of Bile Acids in Individuals with Coronary Artery Disease: Insights from a Systematic Review
  15. Reduced Systemic Levels of Bile Acids in Individuals with Coronary Artery Disease: Insights from a Systematic Review - PMC
  16. Serum total bile acids within the normal range are inversely associated with inflammatory indices and Gensini score in patients with premature coronary artery disease - PubMed
  17. Gut Microbiota-Derived Small Molecules in Atherosclerosis: Biosynthesis, Mechanistic Insights, and Translational Potential - PubMed
  18. The Role of Firmicutes in Coronary Artery Disease: A Taxonomic-Level Meta-Analysis of Mendelian Randomization Studies - PubMed

Original Source(s)

Related Content